Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings

•Chemotherapy induced peripheral neuropathy is a common progressive, and often irreversible, adverse effect of many chemotherapeutic agents.•Currently, there are no effective treatments to prevent or control CIPN and there is limited evidence of effective treatment for chronic CIPN.•There are new me...

Full description

Saved in:
Bibliographic Details
Published inCritical reviews in oncology/hematology Vol. 145; p. 102831
Main Authors Ibrahim, Eiman Y., Ehrlich, Barbara E.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.01.2020
Subjects
Antineoplastic Agents - adverse effects
Bortezomib - adverse effects
Chemotherapy
CIPN
Cisplatin
Humans
Neoplasms - drug therapy
Neuropathy
Oxaliplatin
Paclitaxel
Peripheral Nervous System Diseases - chemically induced
Taxanes
Taxoids - therapeutic use
Vinca alkaloids
Chemotherapy
Oxaliplatin
Paclitaxel
Neuropathy
CIPN
Vinca alkaloids
Taxanes
Cisplatin
Online AccessGet full text

Cover

More Information
Summary:•Chemotherapy induced peripheral neuropathy is a common progressive, and often irreversible, adverse effect of many chemotherapeutic agents.•Currently, there are no effective treatments to prevent or control CIPN and there is limited evidence of effective treatment for chronic CIPN.•There are new mechanisms that need to be highlighted and examined in depth for use in developing effective therapies. Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by many of the most commonly used chemotherapeutic agents, including taxanes, vinca alkaloids, and bortezomib. Pain and sensory abnormalities may persist for months, or even years after the cessation of chemotherapy. The management of CIPN is a significant challenge, as it is not possible to predict which patients will develop symptoms, the timing for the appearance of symptoms can develop anytime during the chemotherapy course, there are no early indications that warrant a reduction in the dosage to halt CIPN progression, and there are no drugs approved to prevent or alleviate CIPN. This review focuses on the etiology of CIPN and will highlight the various approaches developed for prevention and treatment. The goal is to guide studies to identify, test, and standardize approaches for managing CIPN.
Bibliography:EYI and BEE conceived the project, EYI wrote the first draft and both authors edited the manuscript.
AUTHOR CONTRIBUTIONS
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2019.102831